Brief: Brightpath Biotherapeutics And Artisan Bio Announce Research And Licensing Agreement To Accelerate Development Of Brightpath's Novel Allogeneic Ipsc Derived Cell Therapy Platform Across Multiple Indications

BrightPath Biotherapeutics Co

02/05/2023 23:12

May 2 (Reuters) - BrightPath Biotherapeutics Co Ltd
 4594.T :
    * BRIGHTPATH BIOTHERAPEUTICS AND ARTISAN BIO ANNOUNCE
RESEARCH AND
LICENSING AGREEMENT TO ACCELERATE DEVELOPMENT OF BRIGHTPATH'S
NOVEL ALLOGENEIC IPSC DERIVED CELL THERAPY PLATFORM ACROSS
MULTIPLE INDICATIONS
    * ARTISAN BIO: BRIGHTPATH TO RECEIVE NON-EXCLUSIVE RIGHTS TO
ARTISAN'S STAR-CRISPR EDITING PLATFORM
    * ARTISAN BIO: TO GET UPFRONT PAYMENT, RESEARCH MILESTONES,
PLUS
LICENSE FEES, DEVELOPMENT MILESTONES, NET SALES MILESTONES,
ROYALTY ON FUTURE PRODUCTS

Source text for Eikon:  ID:nPncb9Bfna 
Further company coverage:  4594.T 

 ((Reuters.Briefs@thomsonreuters.com;))